Medical Management of Oral Motor Disorders: Dystonia, Dyskinesia and Drug-Induced Dystonic Extrapyramidal Reactions

References

• Clark GT, Koyano K, Browne PA, Oral motor disorders in humans. J Calif Dent Assoc 21(1):19-30, January 1993.
   PubMedGoogle Scholar
• Kato T, Thie NM, et al, Bruxism and orofacial movements during sleep. Dent Clin North Am 45(4):657-84, October 2001.
   PubMedGoogle Scholar
• Winocur E, Gavish A, et al, Oral motor parafunctions among heavy drug addicts and their effects on signs and symptoms of temporomandibular disorders. J Orofac Pain 15(1):56-63, Winter 2001.
   PubMedGoogle Scholar
• Clark GT, Minakuchi H, The role of oral appliances in the management of TMDs. In: D. Laskin, C Green, W. Hylander, eds. Temporomandibular disorders: An evidenced approach to diagnosis and treatment. Chicago, Quintessence Publishing Co, Inc., pp 1-15, 2006.
   Google Scholar
• Defazio G, Abbruzzese G, et al, Epidemiology of primary dystonia. Lancet Neurol 3(11):673-8, November 2004.
   PubMedGoogle Scholar
• Le KD, Nilsen B, Dietrichs E, Prevalence of primary focal and segmental dystonia in Oslo. Neurology 61(9):1294-6, Nov. 11, 2003.
   PubMedGoogle Scholar
• Nutt JG, Muenter MD, et al, Epidemiology of focal and generalized dystonia in Rochester, Minn., Mov Disord 3(3):188-94, 1988.
   PubMed Web of Science ®Google Scholar
• Tolosa E, Marti MJ, Blepharospasm-oromandibular dystonia syndrome (Meige’s syndrome): Clinical aspects. Adv Neurol 49:73-84, 1988.
   PubMedGoogle Scholar
• Gomez-Wong E, Marti MJ, et al, The “geste antagonistique” induces transient modulation of the blink reflex in human patients with blepharo-spasm. Neurosci Lett 251(2):125-8, July 24, 1998.
   PubMedGoogle Scholar
• Blanchet PJ, Abdillahi O, et al, Prevalence of spontaneous oral dyskinesia in the elderly: A reappraisal. Mov Disord 19(8):892-6, August 2004.
   PubMedGoogle Scholar
• Klawans HL, Tanner CM, Goetz CG, Epidemiology and pathophysiology of tardive dyskinesias. Adv Neurol 49:185-97, 1988.
   PubMedGoogle Scholar
• Casey DE, Pathophysiology of antipsychotic drug-induced movement disorders. J Clin Psychiatry 65 Suppl 9:25-8, 2004.
   PubMed Web of Science ®Google Scholar
• Fernandez HH, Friedman JH, Classification and treatment of tardive syndromes. Neurologist 9(1):16-27, January 2003.
   PubMed Web of Science ®Google Scholar
• Chouinard G, New nomenclature for drug-induced movement disorders including tardive dyskinesia. J Clin Psychiatry 65 Suppl 9:9-15, 2004.
   PubMedGoogle Scholar
• Trosch RM, Neuroleptic-induced movement disorders: Deconstructing extrapyramidal symptoms. J Am Geriatr Soc 52(12 Suppl):S266-71, December 2004.
   PubMedGoogle Scholar
• Tarsy D, Baldessarini RJ, Tarazi FI, Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16(1):23-45, 2002.
   PubMed Web of Science ®Google Scholar
• Tarsy D, Neuroleptic-induced extrapyramidal reactions: Classification, description, and diagnosis. Clin Neuropharmacol 6:9-26, 1983,
   PubMed Web of Science ®Google Scholar
• Van Putten T, May PRA, Marder SR, Akathisia with haloperidol and thiothixene. Arch Gen Psychiatry 41:1036-9, 1984.
   PubMed Web of Science ®Google Scholar
• Ellison JM, Stanziani P, SSRI-associated nocturnal bruxism in four patients. J Clin Psychiatry 54(11):432-4, November 1993.
   PubMedGoogle Scholar
• Romanelli F, Adler DA, Bungay KM, Possible paroxetine-induced bruxism. Ann Pharmacother 30(11):1246-8, November 1996.
   PubMedGoogle Scholar
• Gerber PE, Lynd LD, Selective serotonin-reuptake inhibitor-induced movement disorders. Ann Pharmacother 32(6):692-8, June 1998.
   PubMed Web of Science ®Google Scholar
• Lobbezoo F, van Denderen RJ, et al, Reports of SSRI-associated bruxism in the family physician’s office. J Orofac Pain 15(4):340-6, Fall 2001.
   PubMedGoogle Scholar
• Berry RB, Yamaura EM, et al, Acute effects of paroxetine on genioglossus activity in obstructive sleep apnea. Sleep 22(8):1087-92, Dec. 15, 1999.
   PubMed Web of Science ®Google Scholar
• Peroutka SJ, Newman H, Harris H, Subjective effects of 3, 4-methylenedioxymethamphetamine in recreational users. Neuropsychopharmacology 1(4):273-7, December 1988.
   PubMed Web of Science ®Google Scholar
• Vollenweider FX, Gamma A, et al, Psychological and cardiovascular effects and short-term sequelae of MDMA (“ecstasy”) in MDMA-naive healthy volunteers. Neuropsychopharmacology 19(4):241-51, October 1998.
   PubMed Web of Science ®Google Scholar
• Fazzi M, Vescovi P, et al, The effects of drugs on the oral cavity. Minerva Stomatol 48(10):485-92, October 1999.
   PubMedGoogle Scholar
• See SJ, Tan EK, Severe amphethamine-induced bruxism: Treatment with botulinum toxin. Acta Neurol Scand 107(2):161-3, February 2003.
   PubMedGoogle Scholar
• Winocur E, Gavish A, et al, Drugs and bruxism: A critical review. J Orofac Pain 17(2):99-111, Spring 2003.
   PubMedGoogle Scholar
• Malki GA, Zawawi KH, et al, Prevalence of bruxism in children receiving treatment for attention deficit hyperactivity disorder: A pilot study. J Clin Pediatr Dent 29(1):63-7, Fall 2004.
   PubMedGoogle Scholar
• Bressman SB, Dystonia: Phenotypes and genotypes. Rev Neurol (Paris) 159(10 Pt 1):849-56, October 2003.
   PubMedGoogle Scholar
• Sankhla C, Lai EC, Jankovic J, Peripherally induced oromandibular dystonia. J Neurol Neurosurg Psychiatry 65(5):722-8, November 1998.
   PubMedGoogle Scholar
• Schrag A, Bhatia KP, et al, Atypical and typical cranial dystonia following dental procedures. Mov Disord 14(3):492-6, May 1999.
   PubMed Web of Science ®Google Scholar
• Bressman SB, Dystonia update. Clin Neuropharmacol 23(5):239-51, September-October 2000.
   PubMed Web of Science ®Google Scholar
• Scott BL, Evaluation and treatment of dystonia. South Med J 93(8):746-51, August 2000.
   PubMedGoogle Scholar
• Raja M, Managing antipsychotic-induced acute and tardive dystonia. Drug Saf 19(1):57-72, July 1998.
   PubMed Web of Science ®Google Scholar
• Gelenberg AJ, Treating extrapyramidal reactions. Biol Ther Psychiatry 6:13-6, 1983. Gelenberg AJ, Treating extrapyramidal reactions: Some current issues. J Clin Psychiatry 9(Suppl):24-7, 1987.
   Google Scholar
• Donlon PT, Stenson RL, Neuroleptic induced extrapyramidal symptoms. Dis Nerv Sys 37:629-35, 1976.
   PubMedGoogle Scholar
• Borison RL, Amantadine in the management of extrapyramidal side effects. Clin Neuropharmacol 6(Suppl):S57-S63, 1983.
   PubMedGoogle Scholar
• Gagrat D, Hamilton J, Belmaker RH, Intravenous diazepam in the treatment of neuroleptic-induced acute dystonia and akathisia. Am J Psychiatry 135:1232-3, 1978.
   PubMed Web of Science ®Google Scholar
• Pavlovic ZM, Buspirone to improve compliance in venlafaxine-induced movement disorder. Int J Neuropsychopharmacol 7(4):523-4, 2004.
   PubMedGoogle Scholar
• Bostwick JM, Jaffee MS, Buspirone as an antidote to SSRI-induced bruxism in four cases. J Clin Psychiatry 60(12):857-60, December 1999.
   PubMedGoogle Scholar
• Balash Y, Giladi N, Efficacy of pharmacological treatment of dystonia: Evidence-based review including meta-analysis of the effect of botulinum toxin and other cure options. Eur J Neurol 11(6):361-70, June 2004.
   PubMed Web of Science ®Google Scholar
• Rawicki B, Treatment of cerebral origin spasticity with continuous intrathecal baclofen delivered via an implantable pump: Long-term follow-up review of 18 patients. J Neurosurg 91(5):733-6, November 1999.
   PubMedGoogle Scholar
• Ford B, Greene PE, et al, Intrathecal baclofen in the treatment of dystonia. Adv Neurol 78:199-210, 1998.
   PubMedGoogle Scholar
• Kast RE, Tiagabine may reduce bruxism and associated temporomandibular joint pain. Anesth Prog 52(3):102-4, Fall 2005.
   PubMedGoogle Scholar
• Davis TL, Charles PD, Burns RS, Clonazepam-sensitive intermittent dystonic tremor. South Med J 88(10):1069-71, October 1995.
   PubMedGoogle Scholar
• Moore AP, Wood GD, The medical management of masseteric hypertrophy with botulinum toxin type A. Br J Oral Maxillofac Surg 32(1):26-8, February 1994.
   PubMed Web of Science ®Google Scholar
• Daelen B, Thorwirth V, Koch A, Treatment of recurrent dislocation of the temporomandibular joint with type-A botulinum toxin. Int J Oral Maxillofac Surg 26(6):458-60, December 1997.
   PubMedGoogle Scholar
• Gilles R, Magistris MR, et al, Treatment of recurrent luxation of the temporomandibular joint with botulinum toxin]. Rev Stomatol Chir Maxillofac 101(4):189-91, October 2000.
   PubMedGoogle Scholar
• Kane MA, Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg 103(2):656-63, discussion 664-5, February 1999. Erratum in: Plast Reconstr Surg 103(3), March 1999.
   PubMedGoogle Scholar
• Matarasso A, Matarasso SL, et al, Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 103(2):645-52, discussion 653-5, February 1999.
   PubMedGoogle Scholar
• Blitzer A, Brin MF, et al, Botulinum toxin injection for the treatment of oromandibular dystonia. Ann Otol Rhinol Laryngol 98(2):93-7, February 1989.
   PubMed Web of Science ®Google Scholar
• Blitzer A, Brin MF, Fahn S, Botulinum toxin injections for lingual dystonia. Laryngoscope 101(7 Pt 1):799, July 1991.
   PubMedGoogle Scholar
• Charles PD, Davis TL, et al, Tongue protrusion dystonia: Treatment with botulinum toxin. South Med J 90(5):522-5, May 1997.
   PubMedGoogle Scholar
• Nolan J, Chalkiadis GA, et al, Anaesthesia and pain management in cerebral palsy. Anaesthesia 55(1):32-41, January 2000.
   PubMed Web of Science ®Google Scholar
• Clark GT, The management of oromandibular motor disorders and facial spasms with injections of botulinum toxin. Phys Med Rehabil Clin N Am 14(4):727-48, November 2003.
   PubMedGoogle Scholar
• Eleopra R, Tugnoli V, et al, Botulinum toxin treatment in the facial muscles of humans: Evidence of an action in untreated near muscles by peripheral local diffusion. Neurology 46(4):1158-60, April 1996.
   PubMed Web of Science ®Google Scholar
• Wohlfarth K, Schubert M, et al, Remote F-wave changes after local botulinum toxin application. Clin Neurophysiol 112(4):636-40, April 2001.
   PubMed Web of Science ®Google Scholar
• Klein AW, Contraindications and complications with the use of botulinum toxin. Clin Dermatol 22(1):66-75, January-February 2004.
   PubMedGoogle Scholar